Volltext-Downloads (blau) und Frontdoor-Views (grau)
  • search hit 1 of 1
Back to Result List

Open innovation and external sources of innovation : an opportunity to fuel the R&D pipeline and enhance decision making?

  • Historically, research and development (R&D) in the pharmaceutical sector has predominantly been an in-house activity. To enable investments for game changing late-stage assets and to enable better and less costly go/no-go decisions, most companies have employed a fail early paradigm through the implementation of clinical proof-of-concept organizations. To fuel their pipelines, some pioneers started to complement their internal R&D efforts through collaborations as early as the 1990s. In recent years, multiple extrinsic and intrinsic factors induced an opening for external sources of innovation and resulted in new models for open innovation, such as open sourcing, crowdsourcing, public–private partnerships, innovations centres, and the virtualization of R&D. Three factors seem to determine the breadth and depth regarding how companies approach external innovation: (1) the company’s legacy, (2) the company’s willingness and ability to take risks and (3) the company’s need to control IP and competitors. In addition, these factors often constitute the major hurdles to effectively leveraging external opportunities and assets. Conscious and differential choices of the R&D and business models for different companies and different divisions in the same company seem to best allow a company to fully exploit the potential of both internal and external innovations.

Download full text files

Export metadata

Additional Services

Search Google Scholar

Statistics

frontdoor_oas
Metadaten
Author of HS ReutlingenSchuhmacher, Alexander
URN:urn:nbn:de:bsz:rt2-opus4-17669
DOI:https://doi.org/10.1186/s12967-018-1499-2
ISSN:1479-5876
Erschienen in:Journal of translational medicine
Publisher:BioMed Central
Place of publication:London
Document Type:Journal article
Language:English
Publication year:2018
Tag:crowdsourcing; knowledge leverager; open innovation; pharmaceutical industry; public–private partnerships
Volume:16
Page Number:14
First Page:1
Last Page:14
DDC classes:650 Management
Open access?:Ja
Licence (German):License Logo  Creative Commons - CC BY - Namensnennung 4.0 International